Literature DB >> 27717013

Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura.

Jason Brazelton1, Robert A Oster2, Brandi McCleskey1, Jessica Fuller3, Jill Adamski4, Marisa B Marques1.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) has >90% mortality without therapeutic plasma exchange (TPE). Despite TPE, approximately 10% of patients still die, presumably from cardiac ischemia. We sought clinical or laboratory parameters associated with death by reviewing the records of all patients hospitalized with acquired TTP in our institution for 10 years, and collect demographics and results for hemoglobin, platelet count, creatinine, lactate dehydrogenase, transaminases, total bilirubin, creatinine kinase (CK), CK-MB, and troponin I. Sixty-eight patients were admitted 88 times, and 11 died. Survivors and non-survivors were similar in terms of sex, ethnicity, thrombocytopenia, and degree of anemia at presentation, while the latter were older, had worse renal function and higher CK, CK-MB, and troponin I (univariate analysis). However, only troponin I remained significant on multivariate analyses. We propose that patients with TTP should be monitored with troponin I to detect significant myocardial ischemia that could predict death despite TPE.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  TTP; cardiac ischemia; cardiac markers; death; troponin I

Mesh:

Substances:

Year:  2016        PMID: 27717013     DOI: 10.1002/jca.21510

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  9 in total

Review 1.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

2.  Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Wenjing Cao; Konstantine Halkidis; Mohammad S Abdelgawwad; Nicole K Kocher; Bryan Guillory; Lance A Williams; Radhika Gangaraju; Marisa B Marques; X Long Zheng
Journal:  Blood Adv       Date:  2019-12-23

Review 3.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

4.  Lombardy diagnostic and therapeutic network of thrombotic microangiopathy.

Authors:  I Mancini; P Agosti; M Boscarino; B Ferrari; A Artoni; R Palla; M Spreafico; G Crovetti; E Volpato; S Rossini; C Novelli; S Gattillo; L Barcella; M Salmoiraghi; A Falanga; F Peyvandi
Journal:  Orphanet J Rare Dis       Date:  2022-06-23       Impact factor: 4.303

5.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

6.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

7.  Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.

Authors:  Ruinan Lu; Jingrui Sui; X Long Zheng
Journal:  Blood Adv       Date:  2020-11-10

8.  Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Elizabeth M Staley; Wenjing Cao; Huy P Pham; Chong H Kim; Nicole K Kocher; Lucy Zheng; Radhika Gangaraju; Robin G Lorenz; Lance A Williams; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

Review 9.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.